Yuki Kageyama to Prostate-Specific Antigen
This is a "connection" page, showing publications Yuki Kageyama has written about Prostate-Specific Antigen.
Connection Strength
0.410
-
[Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer]. Hinyokika Kiyo. 1996 Mar; 42(3):197-9.
Score: 0.114
-
Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. Prostate. 2007 Jun 01; 67(8):799-807.
Score: 0.062
-
Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy. BJU Int. 2006 Jun; 97(6):1184-9.
Score: 0.058
-
Transrectal ultrasound-guided transperineal 14-core systematic biopsy detects apico-anterior cancer foci of T1c prostate cancer. Int J Urol. 2004 Aug; 11(8):613-8.
Score: 0.051
-
Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells. Am J Physiol Endocrinol Metab. 2004 Jun; 286(6):E927-31.
Score: 0.049
-
Favorable outcome of intraoperative radiotherapy to the primary site in patients with metastatic prostate cancer. Int J Clin Oncol. 2016 Aug; 21(4):764-772.
Score: 0.028
-
History of malignancy is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram. Int J Urol. 2008 Dec; 15(12):1055-60.
Score: 0.017
-
Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer. Prostate. 2008 Oct 01; 68(14):1570-81.
Score: 0.017
-
Three-dimensional combination of transrectal and transperineal biopsies for efficient detection of stage T1c prostate cancer. Int J Clin Oncol. 2006 Apr; 11(2):127-32.
Score: 0.014